Walnut Hill Medical is pleased to announce that David Kravitz, CEO of Organ Recovery Systems, has joined its Board of Directors. With decades of experience in medical technology development, organ transplantation, and healthcare innovation, Mr. Kravitz will provide valuable strategic guidance as Walnut Hill Medical continues its mission of improving patient access to breakthrough treatments.
Mr. Kravitz is a recognized leader in transplantation medtech. In 1998, he founded Organ Recovery Systems, a company dedicated to improving outcomes in transplantation by enhancing donor organ preservation, evaluation, and transportation. Under his leadership, the company developed and commercialized the groundbreaking LifePort Kidney Transporter, a clinical standard of care in renal transplant centers worldwide. This innovation has significantly improved kidney transplant outcomes by enabling recovery of donor organs previously considered not transplantable, lowering the risk of post-transplant complications and hospitalization, improving long-term graft survival, and supporting renal transplant as a scheduled surgery vs. emergent procedure.
Beyond his leadership at Organ Recovery Systems, Mr. Kravitz is a co-inventor of several dozen medical technology patents and has founded multiple medical device companies focused on improving patient care. In recognition of his contributions, he was named to Fast Company magazine’s “Fast 50” list of global entrepreneurs and innovators in 2004.
His passion for organ transplantation is deeply personal—his father received a lifesaving heart transplant in the 1990s, inspiring Mr. Kravitz to dedicate his career to improving transplant success rates. His work has helped shape modern transplant medicine, ensuring that more patients have access to viable, well-preserved organs.
“I am honored to join the Board of Directors at Walnut Hill Medical,” said Mr. Kravitz. “Healthcare innovation and patient-centered care have always been at the core of my work, and I look forward to contributing my expertise to further the company’s mission.”
Chris Hanna, the CEO of Walnut Hill Medical, added, “David Kravitz is a true innovator in the field of organ transplantation. His leadership, vision, and groundbreaking work in medical technology will be invaluable as we continue to expand our services and improve patient access to innovative therapies.”
As a board member, Mr. Kravitz will play a critical role in advising on technology integration, strategic partnerships, and advanced patient access solutions. His expertise will help Walnut Hill Medical remain at the forefront of medical innovation and accessibility.
About Walnut Hill Medical
Walnut Hill Medical is a leading provider of reimbursement strategies, prior authorization, and DME services, dedicated to improving healthcare access and efficiency. Committed to innovation and exceptional customer service, Walnut Hill Medical partners with MedTech companies worldwide to navigate the complex U.S. healthcare commercialization process seamlessly.
